MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from ...

On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...

DA-1241 Demonstrated Direct Hepatic Action in Addition to Its Glucose Lowering EffectPatients Treated with DA-1241 100mg Achieved Statistically Significant Reduction in ALT Levels at Weeks 4 and 8, ...

(RTTNews) - MetaVia Inc. (MTVA), Wednesday announced positive 16-week results from the two-part Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...

Part 1 of this Phase 2a trial is exploring DA-1241, a novel G-Protein-Coupled Receptor 119, or GPR119, agonist compared to placebo, while Part 2 is investigating the efficacy of DA-1241 in ...

DA-1241 100mg showed statistically significant reductions in ALT levels at weeks 4 and 8 (p=0.0159 and p=0.0342, respectively) and a near statistically significant reduction (p=0.0506) at week 16 ...

DA-1241 Demonstrated Direct Hepatic Action in Addition to Its Glucose Lowering Effect Patients Treated with DA-1241 100mg Achieved Statistically Significant Reduction in ALT Levels at Weeks 4 and ...

Ildong Pharmaceutical stated on the 19th that it will supplement the clinical trial data for the oral antiviral drug ...

Report by Parlance: 87% of healthcare leaders interested in AI have yet to implement it. The majority express a strong desire ...